Core Viewpoint - Southbound funds have increased their holdings in Baize Medical (02609.HK) by 216,600 shares on February 27, indicating growing investor interest in the company [1] Group 1: Southbound Fund Activity - In the last 5 trading days, southbound funds have increased their holdings for 5 days, with a total net increase of 4.476 million shares [1] - Over the past 20 trading days, there have been 11 days of net increases, totaling 7.401 million shares [1] - Currently, southbound funds hold 75.921 million shares of Baize Medical, representing 5.75% of the company's issued ordinary shares [1] Group 2: Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [1] - The company offers comprehensive oncology services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations include hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1] - The company also conducts early cancer screening, tumor vaccination, and health management services for potential healthy populations [1] - Baize Medical primarily operates in the Chinese market [1]

Core Insights - Southbound funds increased their holdings in Baize Medical (02609.HK) by 1.6494 million shares on February 13, with a total net increase of 467,400 shares over the last five trading days [1] - Over the past 20 trading days, there have been 11 days of net increases in holdings by southbound funds, totaling 8.016 million shares [1] - As of now, southbound funds hold 73.0944 million shares of Baize Medical, representing 5.54% of the company's total issued ordinary shares [1] Company Overview - Baize Medical Group is primarily engaged in investment and provision of medical-related services, focusing on oncology [1] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations encompass hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1] - Services provided include cancer diagnosis, treatment, rehabilitation, end-of-life care, early cancer screening, cancer vaccination, and health management services for potential healthy populations [1] - The company primarily operates in the Chinese market [1]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Baize Medical (02609.HK) by 1.4748 million shares on February 12, with a total net reduction of 1.5456 million shares over the past five trading days [1] - Over the last 20 trading days, there have been 10 days of net increases in southbound fund holdings, totaling 5.3742 million shares [1] - As of now, southbound funds hold 71.445 million shares of Baize Medical, representing 5.41% of the company's total issued ordinary shares [1] Group 2 - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology medical services [1] - The company offers comprehensive oncology services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations encompass hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Baize Medical (02609.HK) by 327,000 shares on February 10, with a total net reduction of 64,200 shares over the past five trading days [1] - Over the last 20 trading days, there were 11 days of net increases in southbound fund holdings, totaling 7,309,800 shares [1] - As of now, southbound funds hold 74,477,400 shares of Baize Medical, representing 5.64% of the company's total issued ordinary shares [1] Group 2 - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [1] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations include hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1]

Group 1 - The core point of the article highlights the recent trading activity of southbound funds in Baize Medical (02609.HK), indicating a reduction of 705,000 shares on February 5, while showing a net increase of 1,264,800 shares over the past five trading days [1] - Over the last 20 trading days, Baize Medical experienced net purchases from southbound funds on 12 occasions, totaling 7,593,600 shares [1] - As of now, southbound funds hold 72,990,600 shares of Baize Medical, representing 5.53% of the company's total issued ordinary shares [1] Group 2 - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology medical services [1] - The company offers comprehensive cancer care services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations encompass hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1]

Core Viewpoint - Southbound funds have increased their holdings in Baize Medical (02609.HK), indicating growing investor interest in the company within the oncology healthcare sector [1] Group 1: Southbound Fund Activity - On January 28, southbound funds increased their holdings by 220,200 shares of Baize Medical [1] - Over the past 5 trading days, there have been 4 days of net increases, totaling 3,209,400 shares [1] - In the last 20 trading days, there were 14 days of net increases, amounting to 8,824,200 shares [1] - Currently, southbound funds hold 71,705,400 shares of Baize Medical, representing 5.42% of the company's total issued ordinary shares [1] Group 2: Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [1] - The company offers comprehensive oncology services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations encompass hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1] - The company also conducts early cancer screening, tumor vaccination, and health management services for potential healthy populations [1] - Baize Medical primarily operates in the Chinese market [1]

Core Viewpoint - Southbound funds increased their holdings in Baize Medical (02609.HK) by 10,200 shares on December 9, indicating a potential positive sentiment towards the company [1] Group 1: Southbound Fund Activity - Over the past 5 trading days, there was a net reduction of 382,800 shares, with southbound funds reducing their holdings on one day [1] - In the last 20 trading days, there were 10 days of net reductions totaling 2,009,400 shares [1] - Currently, southbound funds hold 62,471,400 shares of Baize Medical, representing 4.73% of the company's total issued ordinary shares [1] Group 2: Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [1] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations include hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1] - The company also conducts early cancer screening, tumor vaccination, and health management services for potential healthy populations, primarily in the Chinese market [1]

Group 1 - The core point of the article is that southbound funds have increased their holdings in Baize Medical (02609.HK) by 132,600 shares on November 21, 2025, with a total net increase of 1,084,000 shares over the past 20 trading days [1][2] - As of now, southbound funds hold a total of 63,736,800 shares of Baize Medical, accounting for 4.82% of the company's total issued ordinary shares [1][2] - The company operates primarily in the oncology medical services sector, providing a full cycle of medical services including screening, diagnosis, treatment, and rehabilitation [2] Group 2 - The trading data shows fluctuations in shareholding over the past few days, with a net increase of 10,920 shares over the last five trading days [2] - The company is involved in various aspects of oncology care, including cancer diagnosis, treatment, rehabilitation, and palliative care, as well as early cancer screening and health management services [2]

Core Insights - Southbound funds increased their holdings in Baize Medical (02609.HK) by 800.16 million shares on September 19, 2025, marking a significant increase in investment interest [1] - Over the past five trading days, Baize Medical has seen a cumulative net increase of 61.66 million shares held by southbound funds, indicating strong demand [1] - As of now, southbound funds hold a total of 64.40 million shares of Baize Medical, representing 4.88% of the company's total issued ordinary shares [1] Trading Data Summary - On September 19, 2025, total shares held reached 64.40 million, with a change of 800.16 million shares, reflecting a 14.19% increase [2] - On September 18, 2025, total shares held were 56.40 million, with a change of 20.24 million shares, showing a 55.96% increase [2] - On September 17, 2025, total shares held were 36.16 million, with a change of 16.90 million shares, indicating an 87.75% increase [2] - On September 16, 2025, total shares held were 19.26 million, with a change of 16.29 million shares, representing a 547.44% increase [2] - On September 15, 2025, total shares held were 2.97 million, with a change of 0.24 million shares, reflecting an 8.66% increase [2] Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology care [2] - The company offers comprehensive oncology services, including screening, diagnosis, treatment, and rehabilitation [2] - Baize Medical's operations include hospital services, hospital management, supply of pharmaceuticals, medical devices, and consumables, as well as other health management services [2] - The company primarily operates in the Chinese market, providing services such as cancer diagnosis, treatment, rehabilitation, and end-of-life care [2]

Core Viewpoint - Baize Medical Group Limited is planning to go public on the Hong Kong Stock Exchange, with a global offering of 133 million shares and an expected fundraising amount between HKD 562 million and HKD 898 million [1][3]. Company Overview - Baize Medical was established in July 2017 and is primarily engaged in investment and provision of medical services related to oncology, operating 8 hospitals across various provinces in China [5][6]. - The company has a registered capital of RMB 1.234 billion and is fully controlled by Beijing Baibai Medical Management [3][5]. Financial Performance - The revenue for Baize Medical for the years 2022, 2023, and 2024 was approximately RMB 803 million, RMB 1.072 billion, and RMB 1.189 billion, respectively, showing a growth trend despite ongoing losses [6][7]. - The net losses for the same years were RMB 75.5 million, RMB 24.4 million, and RMB 3.6 million, indicating a narrowing loss margin [6][8]. - Adjusted net profits (non-IFRS) for the years were approximately -RMB 75.3 million, -RMB 9.6 million, and RMB 12.5 million, with adjusted EBITDA of RMB 35.3 million, RMB 122.3 million, and RMB 135.6 million [8]. Business Operations - The company operates 6 for-profit hospitals and manages 2 non-profit hospitals, focusing on cancer-related medical services, including diagnosis, treatment, rehabilitation, and palliative care [5][6]. - As of December 31, 2024, Baize Medical's hospitals employed 1,119 practicing physicians and had a total of 2,829 medical professionals providing various oncology services [9][10].